Latest Breaking News On - Gynecology reproductive sciences - Page 1 : comparemela.com

Predictive Oncology Announces Positive Results From Ovarian Cancer Study With UPMC Magee-Womens Hospital To Be Presented At The 2024 American Society ...

Study successfully demonstrated Predictive s ability to build AI multi-omic machine learning models to predict survival outcomes among ovarian cancer

United statesBrian orrArlette uihleinRobert edwardsPredictive oncology incGynecology reproductive sciencesAmerican society of clinical oncologyDepartment of obstetricsGynecologic oncology researchWomens hospitalClinical oncologyAnnual meetingPredictive oncologyReproductive sciencesMagee womens hospitalSenior vice president

Intrahepatic Cholestasis of Pregnancy (ICP): Research Into Life-saving Diagnostics Receives Funding

Standard mass spectrometry testing for intrahepatic cholestasis of pregnancy (ICP) can take days, which is sometimes too late. A newer assay can provide test

University of south carolinaSouth carolinaUnited statesJudd william gardnerJoe el khouryBerry allen campbellAllison gardnerYale department of obstetricsYale school of medicine joe el khouryGynecology reproductive sciencesUniversity of south carolina school medicineDrug administrationPrisma healthYale schoolTotal bile acidsReproductive sciences

AIM ImmunoTech Announces Positive Top-Line, Protocol-Planned Interim Report Data from the Study of Ampligen Combined with Pembrolizumab for the Treatment of Recurrent Ovarian Cancer | Company Announcement

Investegate announcements from AIM ImmunoTech Announces Positive Top-Line, Protocol-Planned Interim Report Data from the Study of Ampligen Combined with Pembrolizumab for the Treatment of Recurrent Ovarian Cancer

United statesThomask equelsRobert edwardsUniversity of pittsburgh medical centerGynecology reproductive sciencesGynecologic oncology research at magee womens hospitalExchange commissionImmunotech incDepartment of obstetricsTech announces positive top lineProtocol planned interim report dataAmpligen combinedRecurrent ovarianImmune checkpoint blockadePittsburgh medical centerObjective response rate

AIM ImmunoTech Announces Positive Top-Line, Protocol-Planned Interim Report Data from the Study of Ampligen Combined with Pembrolizumab for the Treatment of Recurrent Ovarian Cancer

OCALA, Fla., April 10, 2024 AIM ImmunoTech Inc. today announced top-line interim data indicating that combining Ampligen with Keytruda in the treatment of recurrent ovarian cancer may have.

United statesRobert edwardsThomask equelsExchange commissionDepartment of obstetricsImmunotech incGynecologic oncology research at magee womens hospitalUniversity of pittsburgh medical centerGynecology reproductive sciencesImmune checkpoint blockadeRecurrent ovarianPittsburgh medical centerObjective response rateClinical benefit rateProgression free survivalReproductive sciences

AIM ImmunoTech (AIM) Announces Positive Top-Line, Protocol-Planned Interim Report Data from the Study of Ampligen Combined with Pembrolizumab for the Treatment of Recurrent Ovarian Cancer

AIM ImmunoTech (AIM) Announces Positive Top-Line, Protocol-Planned Interim Report Data from the Study of Ampligen Combined with Pembrolizumab for the Treatment of Recurrent Ovarian Cancer
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United statesThomask equelsRobert edwardsDepartment of obstetricsImmunotech incGynecologic oncology research at magee womens hospitalGynecology reproductive sciencesUniversity of pittsburgh medical centerImmune checkpoint blockadeRecurrent ovarianPittsburgh medical centerObjective response rateClinical benefit rateProgression free survivalReproductive sciencesGynecologic oncology research